Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CASI

CASI Pharmaceuticals Inc

Dec 23 • 04:00PM ET

0.7532

-0.0471 -5.89 %

Healthcare • Biotechnology • China • NASD

Today, 4:10 PMCASI Pharmaceuticals secures Nasdaq panel extension for continued listing, with deadline extended to Feb 17, 2026 to regain MVLS compliance.

Peers: BMY GILD AMGN MRK PFE JNJ LLY ABBV REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.16	Insider Own	84.60%	Shs Outstand	15.49M	Perf Week	-14.41%
Market Cap	11.67M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.00%	Shs Float	2.39M	Perf Month	-38.76%
Enterprise Value	25.85M	PEG	-	EPS next Q	-0.36	Inst Own	4.13%	Short Float	4.24%	Perf Quarter	-52.33%
Income	-49.38M	P/S	0.43	EPS this Y	-0.78%	Inst Trans	3.85%	Short Ratio	0.91	Perf Half Y	-41.84%
Sales	26.85M	P/B	-	EPS next Y	45.35%	ROA	-106.28%	Short Interest	0.10M	Perf YTD	-73.39%
Book/sh	-1.66	P/C	2.49	EPS next 5Y	18.42%	ROE	-1094.50%	52W High	3.47 -78.29%	Perf Year	-72.00%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	1.69% 11.81%	ROIC	-	52W Low	0.80 -5.85%	Perf 3Y	-57.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.67% 47.19%	Gross Margin	35.80%	Volatility	9.33% 9.80%	Perf 5Y	-97.11%
Dividend TTM	-	EV/Sales	0.96	EPS Y/Y TTM	-42.26%	Oper. Margin	-162.21%	ATR (14)	0.10	Perf 10Y	-92.24%
Dividend Ex-Date	-	Quick Ratio	0.24	Sales Y/Y TTM	26.20%	Profit Margin	-183.93%	RSI (14)	25.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.30	EPS Q/Q	-23.54%	SMA20	-17.10%	Beta	0.82	Target Price	4.00
Payout	-	Debt/Eq	-	Sales Q/Q	-60.54%	SMA50	-39.12%	Rel Volume	0.49	Prev Close	0.80
Employees	233	LT Debt/Eq	-	Earnings	Nov 14 AMC	SMA200	-55.66%	Avg Volume	111.65K	Price	0.75
IPO	Jun 12, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-70.00% -	Trades		Volume	54,156	Change	-5.89%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-21	Initiated	BTIG Research	Buy	$4
Apr-26-21	Initiated	Mizuho	Buy	$3.80
Oct-23-20	Initiated	Oppenheimer	Outperform	$5
Sep-22-16	Initiated	Maxim Group	Buy	$4
Oct-29-15	Resumed	H.C. Wainwright	Buy	$2.50 → $3
Jun-23-15	Initiated	H.C. Wainwright	Buy	$2.50

Today 04:05PM	CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements (ACCESSWIRE) -5.89%
Dec-11-25 09:00AM	CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing (ACCESSWIRE) +10.85%
Dec-08-25 09:00AM	CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting (ACCESSWIRE)
Nov-19-25 09:00AM	CASI Pharmaceuticals Announces Changes in Board Governance (ACCESSWIRE)
Nov-14-25 04:05PM	CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results (ACCESSWIRE) -5.62% -5.56%
04:05PM	Loading…
Nov-10-25 04:05PM	CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ (ACCESSWIRE)
Nov-04-25 09:00AM	CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference (ACCESSWIRE)
Nov-03-25 09:01AM	CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting (ACCESSWIRE)
Sep-26-25 09:45AM	CASI Pharmaceuticals Appoints James Huang to Board of Directors (ACCESSWIRE) -13.30%
Sep-08-25 09:00AM	CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study (ACCESSWIRE)
Sep-03-25 09:00AM	CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference (ACCESSWIRE)
Sep-02-25 09:00AM	CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors (ACCESSWIRE)
Aug-29-25 04:05PM	CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results (ACCESSWIRE) -5.33%
Aug-28-25 09:00AM	CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 (ACCESSWIRE) +9.42%
Aug-27-25 05:20PM	Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
09:15AM	Loading…
Aug-14-25 09:15AM	VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.01%
Aug-13-25 05:25PM	VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-12-25 06:25PM	Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 05:55PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -12.50% +10.88%
Aug-06-25 08:55AM	Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates (Zacks) -13.40%
Aug-04-25 09:00AM	CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) (ACCESSWIRE) +51.16%
Jul-31-25 08:15AM	Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates (Zacks) -14.47%
Jul-21-25 04:05PM	CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program (ACCESSWIRE)
May-19-25 09:00AM	CASI Pharmaceuticals Provides Business and Clinical Update (ACCESSWIRE)
May-16-25 08:00AM	CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results (ACCESSWIRE) +7.23%
May-12-25 05:15PM	Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China (ACCESSWIRE)
May-07-25 08:00AM	CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement (ACCESSWIRE)
Mar-31-25 08:15AM	CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results (ACCESSWIRE)
Jan-06-25 08:00AM	CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia (ACCESSWIRE) +6.94%
08:00AM	Loading…
Nov-15-24 08:00AM	CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results (ACCESSWIRE) -9.35%
Nov-13-24 07:29AM	CASI Pharmaceuticals Inc (CASI) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-24-24 08:00AM	CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia (ACCESSWIRE) +6.00%
Sep-04-24 08:00AM	CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE (PR Newswire)
Aug-16-24 08:00AM	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS (PR Newswire)
Jul-29-24 03:04PM	3 Promising Biotech Stocks You Can Pick Up for Less Than $10 (InvestorPlace) +6.06%
Jul-19-24 05:30PM	CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS (PR Newswire) -5.51%
Jul-08-24 07:30AM	CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP (PR Newswire) +13.61%
Jun-27-24 09:42AM	CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business (Zacks) +36.68%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 04:15PM	CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company (PR Newswire)
04:10PM	CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He (PR Newswire)
May-15-24 11:04AM	CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study (MT Newswires)
08:00AM	CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) (PR Newswire)
May-14-24 01:54PM	CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +23.59%
08:00AM	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS (PR Newswire)
Apr-08-24 05:00PM	CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS (PR Newswire)
Mar-28-24 12:53PM	CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +20.33%
07:00AM	CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS (PR Newswire)
Mar-05-24 07:00AM	CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China (PR Newswire) +11.31%
Feb-16-24 07:00AM	CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN IN CHINA (PR Newswire)
Nov-14-23 07:00AM	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES (PR Newswire)
Nov-08-23 07:00AM	CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA (PR Newswire)
Aug-11-23 07:00AM	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES (PR Newswire)
Aug-01-23 07:00AM	Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals (PR Newswire)
Jul-20-23 08:00AM	CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 (PR Newswire) -6.34%
May-28-23 08:35AM	We Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-17-23 07:35AM	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire) -7.48%
Apr-26-23 09:35AM	CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 (PR Newswire)
07:00AM	CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS (PR Newswire)
Apr-17-23 07:11AM	Improved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justified (Simply Wall St.) -8.08%
Mar-21-23 04:30PM	CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER (PR Newswire) +9.82%
Feb-06-23 08:07AM	A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last year (Simply Wall St.)
Jan-06-23 08:42AM	Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China (MarketWatch)
07:00AM	CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA (PR Newswire)
Dec-15-22 07:00AM	CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (PR Newswire)
Nov-17-22 05:39AM	CASI Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 08:15AM	CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Sep-23-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET (PR Newswire) -22.26%
Sep-07-22 07:00AM	CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA (PR Newswire)
Aug-12-22 08:35AM	CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.77%
07:00AM	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
06:25AM	Even after rising 58% this past week, CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still down 88% over the past three years (Simply Wall St.)
Aug-05-22 08:38AM	CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 (PR Newswire)
Jul-08-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION (PR Newswire)
Jun-02-22 06:34AM	CASI Pharmaceuticals stock falls after reverse split takes effect (MarketWatch) -8.69%
May-26-22 04:30PM	CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT (PR Newswire) +11.56% -28.89%
May-25-22 07:53AM	A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 10% last year (Simply Wall St.) +12.49%
May-24-22 07:00AM	CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD (PR Newswire) +9.28%
May-12-22 08:15AM	CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.92%
07:00AM	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
May-10-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-02-22 10:15AM	Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth? (Simply Wall St.)
07:00AM	CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 (PR Newswire)
Apr-01-22 07:27AM	China Weighs Giving U.S. Full Access to Audits of Most Firms (Bloomberg) -12.81%
07:00AM	CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT (PR Newswire)
Mar-31-22 07:15PM	Analysts Expect Breakeven For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Before Long (Simply Wall St.) -8.99%
04:54AM	Baidu Added to SEC List of Firms Facing Possible Delisting (Bloomberg)
Mar-28-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE (PR Newswire) +7.03%
Mar-23-22 07:00AM	CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022 (PR Newswire)
Mar-04-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA (PR Newswire)
Feb-23-22 04:36AM	Shareholders in CASI Pharmaceuticals (NASDAQ:CASI) are in the red if they invested three years ago (Simply Wall St.)
Feb-16-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES (PR Newswire)
Feb-15-22 05:03PM	8 Medical Stocks to Buy According to Mitchell Blutts Consonance Capital (Insider Monkey) +11.05%
Jan-20-22 08:50AM	Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag (Benzinga)
07:00AM	CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (PR Newswire)
Jan-18-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA (PR Newswire) -6.05%
Jan-09-22 07:28AM	How Many CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Do Institutions Own? (Simply Wall St.)
Jan-03-22 07:00AM	CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE (PR Newswire) +5.74%

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CASI

CASI Pharmaceuticals Inc

Upgrade your FINVIZ experience